Breckenridge announced that the Food and Drug Administration (FDA) has granted final approval of the Abbreviated New Drug Application for Repaglinide Tablets, the generic version of Novo Nordisk’s Prandin.

Prandin is a meglitinide analogue indicated as an adjunct to diet and exercise in type 2 diabetes, as monotherapy or with metformin or thiazolidinediones. 

Prandin works by lowering blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations.

Repaglinide Tablets will be available in 0.5-mg, 1-mg and 2-mg strengths. Breckenridge plans to ship the product shortly.

For more information call (561) 443-3314 or visit

This article originally appeared on MPR